<DOC>
	<DOCNO>NCT00552071</DOCNO>
	<brief_summary>The purpose study determine difference drug level Sandostatin IM injection Sandostatin LAR without ultrasound guidance ( standard care ) compare drug level Sandostatin IM injection Sandostatin LAR ultrasound guidance subject Acromegaly .</brief_summary>
	<brief_title>Ultrasound Guided Sandostatin LAR Injection Acromegaly</brief_title>
	<detailed_description>IM intragluteal injection report inaccurate placement intramuscular compartment perform dictate current standard care . This inaccuracy placement may effect efficacy drug deliver IM route . Furthermore , inaccuracy IM injection find directly relate BMI find inaccurate female subject . Ultrasound guidance IM injection improve accuracy placement IM injection may improve drug level efficacy Sandostatin LAR treatment Acromegaly .</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Male female patient â‰¥18 year old Patients active acromegaly due pituitary adenoma . Historical data indicate diagnosis acromegaly base circulate IGFI concentration elevate compare age gender match control OR GH &gt; 1 mcg/l 120 Minutes two hour OGTT . Currently treat Sandostatin LAR treat stable dose 3 month prior entry study . Patients diabetes may include , blood glucose diabetic treatment monitor closely trial subject Patients provide write informed consent Uncontrolled diabetes mellitus Patients pregnant lactating Patients know hypersensitivity Sandostatin acetate relate drug compound Patients current gallstone Patients past current history cancer , except basal cell carcinoma situ cancer cervix Patients history hepatic disease ( patient minimal , i.e. , &lt; 3Xs upper limit normal LFTs indicative hepatic steatosis , MAY participate ) Patients receive glucocorticoid therapy within past 6 month , currently receive chemotherapeutic agent , exogenous growth hormone therapy Patients receive investigational drug administer receive within 30 day study entry Patients unacceptable concomitant diagnosis , receive medication and/or therapy ( i.e. , concomitant illness therapy would place patient increase risk , would , opinion investigator sponsor , interfere evaluation efficacy safety ) Interruption discontinuation treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>Octreotide LAR</keyword>
	<keyword>Ultrasound guidance</keyword>
</DOC>